Generic Drug Pricing Transparency Could Reduce Spending, Study Says
Every $1 reduction in the average reimbursement for a generic prescription would reduce US healthcare spending by $4bn, according to a study from Brookings, which concludes more generic drug pricing information should be selectively available to third-party payers.
You may also be interested in...
With US generic drug price erosion running at double digits, 2017 is expected to be a challenging year for the generic drug sector. Manufacturers are looking increasingly to complex generics, injectables and biosimilars as an offset, but it's unclear if wins in those areas will be enough to bridge the growth divide.
For every $100 spent at retail pharmacies, $41 accrues to the manufacturer and $41 accrues to intermediaries in the distribution system, according to a new study on US prescription drug spending, though drug manufacturers hold onto more profit.
The US FDA approved the first antibody cocktail for ebolavirus infection, supporting a supply contract with BARDA. The development experience informed Regeneron's work in COVID-19.